Novo Nordisk Advances Next-Gen Obesity Treatments with LX9851 Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 23 2026
0mins
Should l Buy NVO?
Source: stocktwits
- Clinical Trial Initiation: Novo Nordisk has announced the initiation of a Phase 1 study for LX9851, an oral non-incretin drug candidate from Lexicon Pharmaceuticals aimed at treating obesity and related metabolic disorders, marking a significant advancement in the company's obesity treatment efforts.
- Milestone Payment Triggered: The start of this trial triggers a second $10 million milestone payment to Lexicon under their licensing agreement signed in March 2025, granting Novo Nordisk exclusive global rights to develop and commercialize the drug, with Lexicon eligible for up to $1 billion in total milestone payments and royalties on future sales.
- Trial Scale and Timeline: The Phase 1 study will evaluate safety and dosing in 96 overweight or obese participants, expected to be completed by early 2027, demonstrating Novo Nordisk's commitment and strategic planning in advancing its drug pipeline.
- Market Reaction and Outlook: While NVO shares fell 1.5%, LXRX's stock rose about 1% in pre-market trading, reflecting market optimism regarding the new drug development and enhancing Novo Nordisk's competitive position in the obesity treatment market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 36.750
Low
42.00
Averages
54.67
High
70.00
Current: 36.750
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk's Wegovy Recommended for UK Patients
- Expanded Patient Base: The UK's National Institute for Health and Care Excellence (NICE) has recommended Novo Nordisk's GLP-1 drug Wegovy (semaglutide) for over 1 million patients to prevent strokes and heart attacks, particularly targeting overweight individuals with elevated risks or circulation issues in the legs.
- Clinical Data Support: NICE noted that clinical trial data indicated Wegovy is associated with a reduced risk of heart attack, stroke, or cardiovascular death, with benefits observed even before significant weight loss, highlighting the drug's early efficacy.
- New Indication Coverage: The new recommendations apply to adults who have previously suffered a heart attack or stroke, or have peripheral arterial disease or a body mass index of at least 27, with an estimated 1.2 million people eligible to use semaglutide to mitigate the risk of further heart attacks or strokes.
- Additional Layer of Protection: NICE stated that today's decision provides an extra layer of protection for those who have already experienced heart attacks or strokes, helping to alleviate their fears of recurrence while complementing their existing medications.
See More
Indian Markets Rattle Amid Iran War Turmoil
- Foreign Capital Exodus: Amid the turmoil of the Iran war, Indian markets experienced a record foreign investor sell-off exceeding $12 billion in March, resulting in a more than 10% drop in the Nifty 50 index, highlighting significant concerns over future economic growth prospects.
- Diminished Growth Outlook: India's Chief Economic Advisor V. Anantha Nageswaran warned that rising energy costs and supply chain disruptions pose considerable downside risks to the forecasted 7.0%-7.4% growth for FY 2027, with expectations of a significant widening of the trade deficit exacerbating fiscal pressures.
- Government Intervention: In response to economic strains, the Indian government implemented two key measures, including limiting banks' currency-hedging positions and cutting excise duties on petrol and diesel by 10 rupees per liter, which will significantly impact tax revenues and potentially hinder government spending capabilities.
- Weak Job Market: While India's consumption narrative continues to attract foreign investment, the lack of white-collar job creation undermines this story, with reports indicating that only a small percentage of graduates secure stable employment within a year of graduation, posing a long-term challenge to economic growth.
See More
Eli Lilly Secures FDA Approval for New Weight-Loss Drug
- FDA Approval: Eli Lilly announced that its weight-loss drug Foundayo received FDA approval, becoming the first daily oral weight-loss medication, which is expected to be highly popular and pushed the stock price up nearly 4%, significantly outperforming the S&P 500's 0.7% gain.
- Product Launch Plan: The new drug will start shipping on April 6 through Eli Lilly's LillyDirect online sales platform, with a minimum self-pay option of $149 per month, likely attracting many consumers seeking weight-loss solutions and further increasing the company's market share.
- Market Competition Analysis: Compared to Novo Nordisk's Wegovy, Foundayo has lower reported weight-loss results in clinical trials, but its more stable molecule and flexible dosing schedule may make it more appealing to consumers, enhancing its competitive edge in the market.
- Significant Marketing Potential: Eli Lilly possesses substantial marketing resources, which are expected to effectively drive the acceptance of Foundayo in the market; combined with its leadership position in the weight-loss drug sector, this could lead to a notable increase in stock price.
See More
Eli Lilly Wins FDA Approval for Foundayo Weight-Loss Pill
- FDA Approval: Eli Lilly has received FDA approval for its weight-loss drug Foundayo, which is a daily oral medication, marking a significant breakthrough for the company in the weight-loss market and is expected to attract a large consumer base.
- Positive Market Reaction: The announcement led to a nearly 4% increase in Eli Lilly's stock price, significantly outperforming the S&P 500's 0.7% gain, indicating strong investor confidence in the new product.
- Clear Product Advantages: Foundayo offers a sturdier molecular structure and more flexible dosing compared to Novo Nordisk's Wegovy, although it has shown slightly lower weight-loss results in clinical trials; however, its convenience may attract more users.
- Innovative Sales Channel: The new drug will start shipping on April 6 through Eli Lilly's LillyDirect online sales platform, with a minimum self-pay option of $149 per month, which is expected to enhance the company's market share and brand influence.
See More
Eli Lilly Receives FDA Approval for New Drug Foundayo
- New Drug Approval: Eli Lilly announced that its once-daily GLP-1 drug Foundayo has received FDA approval and is set to launch on April 6 via the LillyDirect online platform, addressing strong market demand for weight loss medications and further solidifying its position in the obesity treatment market.
- Positive Market Outlook: Analysts forecast Foundayo to generate approximately $1.55 billion in sales this year, with projections growing to about $14.8 billion by 2030, indicating the drug's significant potential in the future market and its capacity to reshape obesity treatment paradigms.
- Significant Competitive Advantage: Compared to rival Novo Nordisk's Wegovy, Foundayo offers greater flexibility in dosing and dietary restrictions, and has demonstrated superior efficacy in clinical studies for diabetes patients, which may attract a broader patient base to choose this medication.
- Accelerated Strategic Transformation: Eli Lilly built up a substantial stockpile of the drug ahead of FDA approval to ensure a swift market response, showcasing the company's foresight and execution in its new drug launch strategy, thereby enhancing its competitiveness in the biopharmaceutical industry.
See More
Novo Nordisk's New Drug Approval May Aid Market Comeback
- New Drug Approval: On March 19, Novo Nordisk announced FDA approval for a high-dose version of Wegovy, which demonstrated an average weight loss of 18.8% in clinical trials, surpassing the original's 15.5%, potentially aiding the company's competitive position in the weight-loss market.
- Increased Competitive Pressure: Although HD Wegovy outperforms the original formulation, it still falls short of Eli Lilly's Zepbound, which achieved a 20.2% weight loss in head-to-head studies, highlighting the challenges Novo Nordisk faces in regaining market leadership.
- Multiple Indication Advantage: Zepbound's approval for treating obstructive sleep apnea in overweight patients provides it with an additional edge, further complicating Novo Nordisk's efforts to reclaim its top position in the market.
- Future Potential: Novo Nordisk has promising candidates like Amycretin and UBT251 in its pipeline, and positive clinical trial results could boost its stock price, although immediate recovery of market leadership appears unlikely.
See More
Novo Nordisk's Wegovy Recommended for UK Patients
- Expanded Patient Base: The UK's National Institute for Health and Care Excellence (NICE) has recommended Novo Nordisk's GLP-1 drug Wegovy (semaglutide) for over 1 million patients to prevent strokes and heart attacks, particularly targeting overweight individuals with elevated risks or circulation issues in the legs.
- Clinical Data Support: NICE noted that clinical trial data indicated Wegovy is associated with a reduced risk of heart attack, stroke, or cardiovascular death, with benefits observed even before significant weight loss, highlighting the drug's early efficacy.
- New Indication Coverage: The new recommendations apply to adults who have previously suffered a heart attack or stroke, or have peripheral arterial disease or a body mass index of at least 27, with an estimated 1.2 million people eligible to use semaglutide to mitigate the risk of further heart attacks or strokes.
- Additional Layer of Protection: NICE stated that today's decision provides an extra layer of protection for those who have already experienced heart attacks or strokes, helping to alleviate their fears of recurrence while complementing their existing medications.
See More
Indian Markets Rattle Amid Iran War Turmoil
- Foreign Capital Exodus: Amid the turmoil of the Iran war, Indian markets experienced a record foreign investor sell-off exceeding $12 billion in March, resulting in a more than 10% drop in the Nifty 50 index, highlighting significant concerns over future economic growth prospects.
- Diminished Growth Outlook: India's Chief Economic Advisor V. Anantha Nageswaran warned that rising energy costs and supply chain disruptions pose considerable downside risks to the forecasted 7.0%-7.4% growth for FY 2027, with expectations of a significant widening of the trade deficit exacerbating fiscal pressures.
- Government Intervention: In response to economic strains, the Indian government implemented two key measures, including limiting banks' currency-hedging positions and cutting excise duties on petrol and diesel by 10 rupees per liter, which will significantly impact tax revenues and potentially hinder government spending capabilities.
- Weak Job Market: While India's consumption narrative continues to attract foreign investment, the lack of white-collar job creation undermines this story, with reports indicating that only a small percentage of graduates secure stable employment within a year of graduation, posing a long-term challenge to economic growth.
See More
Eli Lilly Secures FDA Approval for New Weight-Loss Drug
- FDA Approval: Eli Lilly announced that its weight-loss drug Foundayo received FDA approval, becoming the first daily oral weight-loss medication, which is expected to be highly popular and pushed the stock price up nearly 4%, significantly outperforming the S&P 500's 0.7% gain.
- Product Launch Plan: The new drug will start shipping on April 6 through Eli Lilly's LillyDirect online sales platform, with a minimum self-pay option of $149 per month, likely attracting many consumers seeking weight-loss solutions and further increasing the company's market share.
- Market Competition Analysis: Compared to Novo Nordisk's Wegovy, Foundayo has lower reported weight-loss results in clinical trials, but its more stable molecule and flexible dosing schedule may make it more appealing to consumers, enhancing its competitive edge in the market.
- Significant Marketing Potential: Eli Lilly possesses substantial marketing resources, which are expected to effectively drive the acceptance of Foundayo in the market; combined with its leadership position in the weight-loss drug sector, this could lead to a notable increase in stock price.
See More
Eli Lilly Wins FDA Approval for Foundayo Weight-Loss Pill
- FDA Approval: Eli Lilly has received FDA approval for its weight-loss drug Foundayo, which is a daily oral medication, marking a significant breakthrough for the company in the weight-loss market and is expected to attract a large consumer base.
- Positive Market Reaction: The announcement led to a nearly 4% increase in Eli Lilly's stock price, significantly outperforming the S&P 500's 0.7% gain, indicating strong investor confidence in the new product.
- Clear Product Advantages: Foundayo offers a sturdier molecular structure and more flexible dosing compared to Novo Nordisk's Wegovy, although it has shown slightly lower weight-loss results in clinical trials; however, its convenience may attract more users.
- Innovative Sales Channel: The new drug will start shipping on April 6 through Eli Lilly's LillyDirect online sales platform, with a minimum self-pay option of $149 per month, which is expected to enhance the company's market share and brand influence.
See More
Eli Lilly Receives FDA Approval for New Drug Foundayo
- New Drug Approval: Eli Lilly announced that its once-daily GLP-1 drug Foundayo has received FDA approval and is set to launch on April 6 via the LillyDirect online platform, addressing strong market demand for weight loss medications and further solidifying its position in the obesity treatment market.
- Positive Market Outlook: Analysts forecast Foundayo to generate approximately $1.55 billion in sales this year, with projections growing to about $14.8 billion by 2030, indicating the drug's significant potential in the future market and its capacity to reshape obesity treatment paradigms.
- Significant Competitive Advantage: Compared to rival Novo Nordisk's Wegovy, Foundayo offers greater flexibility in dosing and dietary restrictions, and has demonstrated superior efficacy in clinical studies for diabetes patients, which may attract a broader patient base to choose this medication.
- Accelerated Strategic Transformation: Eli Lilly built up a substantial stockpile of the drug ahead of FDA approval to ensure a swift market response, showcasing the company's foresight and execution in its new drug launch strategy, thereby enhancing its competitiveness in the biopharmaceutical industry.
See More
Novo Nordisk's New Drug Approval May Aid Market Comeback
- New Drug Approval: On March 19, Novo Nordisk announced FDA approval for a high-dose version of Wegovy, which demonstrated an average weight loss of 18.8% in clinical trials, surpassing the original's 15.5%, potentially aiding the company's competitive position in the weight-loss market.
- Increased Competitive Pressure: Although HD Wegovy outperforms the original formulation, it still falls short of Eli Lilly's Zepbound, which achieved a 20.2% weight loss in head-to-head studies, highlighting the challenges Novo Nordisk faces in regaining market leadership.
- Multiple Indication Advantage: Zepbound's approval for treating obstructive sleep apnea in overweight patients provides it with an additional edge, further complicating Novo Nordisk's efforts to reclaim its top position in the market.
- Future Potential: Novo Nordisk has promising candidates like Amycretin and UBT251 in its pipeline, and positive clinical trial results could boost its stock price, although immediate recovery of market leadership appears unlikely.
See More
